Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

Study Purpose

The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Observational [Patient Registry]
Eligible Ages	1 Year and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Signed inform consent.

- Histolgically verified solid tumour.

- Receiving systemic therapy for neoplasm.

- Has archival tumour tissue.

- Provide biosamples with living tumour tissue or blood samples for immunologic assessment.

Exclusion Criteria:

- Concurrent Lymphoprolipherative disorder.

- Patients after stem cell or bone marrow thansplantation.

- Incomplete informaton on previous cancer history or medical history.

- Patients with known primary immunodeficiency.

- Patients receiving immunosupressive therapy for concurrent illness.

- Pregnant patients

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT05539677
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	N.N. Petrov National Medical Research Center of Oncology
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Irina Baldueva, MD, PhD, DSc
Principal Investigator Affiliation	N.N. Petrov NMRC of Oncology
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Recruiting
Countries	Russian Federation
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Malignant Solid Tumors, Primary Brain Tumor, Melanoma, Soft Tissue Sarcoma, Colorectal Cancer, Kidney Cancer, Prostate Cancer

Arms & Interventions

Arms

: Melanoma

: Soft tissue sarcoma

: Kidney cancer

: Primary brain tumors

: Malignant neoplasms

: Prostate cancer

: Colorectal cancer

Interventions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.